Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would...
Health
AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
South China Morning Post
The Perspectives
0 verified voices · Three viewpoints · Real discourse
Only verified Neural Identity holders can participate in The Perspectives.
Sign In with Neural Identity
Left
0
Be the first to share a left perspective
Center
0
Be the first to share a center perspective
Right
0
Be the first to share a right perspective
